Neumora Therapeutics (NMRA) Assets Average (2023 - 2026)

Neumora Therapeutics' Assets Average history runs 4 years deep, the most recent figure standing at $172.5 million for Q1 2026.

• In Q1 2026, Assets Average fell 39.88% year-over-year to $172.5 million; the TTM figure through Mar 2026 stood at $172.5 million (down 39.88% YoY), while the FY2025 annual figure was $254.0 million, down 37.53% from the prior year.
• Assets Average for Q1 2026 stood at $172.5 million, down from $184.4 million in the prior quarter.
• The five-year high for Assets Average was $520.5 million in Q4 2023, with the low at $172.5 million in Q1 2026.
• The 4-year median for Assets Average is $310.8 million (2024), against an average of $321.9 million.
• The sharpest annual moves came in 2024 and 2025: Assets Average slumped 35.68% in 2024, then slumped 46.94% in 2025.
• Neumora Therapeutics' Assets Average stood at $520.5 million in 2023, then plunged by 35.68% to $334.8 million in 2024, then plunged by 44.9% to $184.4 million in 2025, then decreased by 6.49% to $172.5 million in 2026.
• Business Quant data shows NMRA's Assets Average at $172.5 million in Q1 2026, $184.4 million in Q4 2025, and $200.8 million in Q3 2025.